CHI3L1 and cancer: In the total cohort, negative (‘0’) YKL-40 expression was found in 15.9% of all cancers, low (‘1’) in 20%, intermediate-low (‘2’) in 33.6%, intermediate-high (‘3’) in 22.2%, and high expression (‘4’) in 8.4% of the cancers (Table 1 and Fig. 2).